ST-elevation Myocardial Infarction Clinical Trial
Official title:
Strategic Target Temperature Management in Myocardial Infarction
The primary goal in the treatment of acute myocardial infarction is to reperfuse the ischemic
myocardium to reduce infarct size. Animal data and human data suggest that whole-body cooling
to temperatures below 35°C before revascularisation can additionally reduce infarct size and
therefore improves outcome in these patients.
The purpose of the study is to determine if a combined cooling strategy started in the
out-of-hospital arena is able to reduce infarct size in acute myocardial infarction.
Background: Contemporary therapy in patients with an on-going ST-elevation myocardial
infarction (STEMI) is to reperfuse the ischemic myocardium as soon as possible to reduce
infarct size and associated complications. A recent pilot-study showed a significant
reduction in infarct size by the induction of pre-reperfusion hypothermia.
Objectives: To demonstrate a reduction in infarct size/myocardium at risk (measured by magnet
resonance imaging) in patients with ST-Elevation myocardial infarction by strategic
temperature management with the use of external cooling pads in the out-of-hospital setting
and the continuation with cold saline and central venous catheter cooling in hospital. In a
parallel translational study, the molecular effects of rapid and early cooling on
inflammatory processes at the culprit lesion site will be defined.
Methodology: Randomized, prospective, controlled trial Number of subjects: 120 patients (60
per group) Investigational medical device: EMCOOLS flex pad is an external cooling pad, that
consists of multiple cooling cells filled with a patented cooling gel. EMCOOLS flex pad will
be used in the out-of-hospital setting to initiate cooling. The Philips RTx Endovascular
Systemâ„¢ is an endovascular thermal control system that circulates cooled saline through an
indwelling central venous catheter in a closed-loop manner. It will be used in combination
with 1-2 litres of intravenous cold saline to induce hypothermia below 35 degrees Celsius.
Duration: One hour after successful revascularization the cooling procedure will be stopped,
subjects will be covered with a blanket and are allowed to passively re-warm. Clinical
follow-up for 180 days.
Primary endpoint: Myocardial infarct size (as a percentage of myocardium at risk) assessed by
cardiac MRI at 4±2 days. Influence of target temperature management on coronary macrophages
and monocytes as well as impact on plasma levels of immune cell chemotaxis and activation.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01864343 -
Target Temperature Management In Myocardial Infarction - A Pilot Study
|
N/A | |
| Completed |
NCT00962416 -
Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI)
|
Phase 4 | |
| Active, not recruiting |
NCT00927615 -
Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)
|
N/A | |
| Completed |
NCT03135275 -
MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial
|
N/A | |
| Recruiting |
NCT02592694 -
Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty
|
Phase 4 | |
| Withdrawn |
NCT01991366 -
Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
|
||
| Completed |
NCT02158468 -
Effect of Conditioning on Myocardial Damage in STEMI
|
N/A | |
| Completed |
NCT01197729 -
OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry
|
N/A | |
| Completed |
NCT06426537 -
Colchicine's Efficacy in MI Patients: Comparing PCI and Non-Reperfusion Approaches
|
Early Phase 1 | |
| Completed |
NCT01882179 -
Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size
|
Phase 3 | |
| Terminated |
NCT00719914 -
A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks
|
Phase 2 | |
| Completed |
NCT00952224 -
Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance - Impact on Outcome
|
N/A | |
| Completed |
NCT00378391 -
European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry
|
N/A | |
| Withdrawn |
NCT04303377 -
Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction
|
Phase 2 | |
| Completed |
NCT03523624 -
Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
|
||
| Completed |
NCT01531114 -
PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus
|
Phase 3 | |
| Active, not recruiting |
NCT01960933 -
Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization
|
N/A | |
| Completed |
NCT00502528 -
Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction
|
Phase 2 | |
| Recruiting |
NCT02062554 -
Brasilia Heart Study
|
||
| Recruiting |
NCT04150016 -
In-stent Repair and Vessel Reaction of STEMI Patients With OCT
|
N/A |